August 16, 2011Journal of Clinical Oncology1,111 citationsOpen Access
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Although AVAGAST did not reach its primary objective, adding bevacizumab to chemotherapy was associated with significant increases in progression-free survival and overall response rate in the first-line treatment of advanced gastric cancer.